GSK plc (GSK) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

Total Assets Chart for GSK plc

GSK plc (GSK) total assets for FY2025 were GBP 61.1B, a 2.8% change from FY2024. GSK plc's total assets grew from GBP 1.8B in 1986 to GBP 61.1B in 2025 (3289.8% over 39 years). Total assets compound annual growth rate: 5-year CAGR of -5.3%, 10-year CAGR of 1.4%, 20-year CAGR of 4.1%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (British Pounds)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
£74.16B
Implied Share Price
£18.52
Enterprise Value
£87.93B
Revenue (TTM)
£33.20B
EBITDA
£10.82B
Profit Margin
14.52%
Trailing P/E
15.69
Forward P/E
19.76
Price/Book (MRQ)
4.13
Price/Sales (TTM)
2.23
EV/EBITDA
9.09
EV/Revenue
2.65
Dividend Yield
3.74%
Book Value
£4.40
Free Cash Flow (FY2025)
£5.96B
Free Cash Flow Yield
8.03%

Snapshot as of 18th August 2026 — not point-in-time controlled, may lag the live market by a few days.